Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3313284 | 0.84 | CNR2 (0.49) | CNR2KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3309833 | 0.83 | MAPT (0.57) | KDM4EMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL3314277 | 0.82 | MAPT (0.48) | KDM4EMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL3311483 | 0.81 | MAPT (0.49) | MAPTTP53 | |
| SCHEMBL3316094 | 0.78 | AKR1A1 (0.51) | KDM4EMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL3312906 | 0.77 | TP53 (0.51) | KDM4EMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL3308047 | 0.75 | MDM2 (0.63) | KDM4EMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL3311370 | 0.73 | CMA1 (0.44) | CNR2KDM4EMEN1KMT2AMAPT | |
| SCHEMBL13361539 | 0.72 | MDM2 (0.59) | KDM4EMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL3314281 | 0.72 | MDM2 (0.54) | KDM4EMEN1KMT2ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012164103-A2 | BLOCKERS OF THE NOGO-A S1PR PATHWAY FOR THE TREATMENT OF DISEASES CHARACTERIZED BY NEURONAL DAMAGE AND LACK OF SUBSEQUENT REPAIR | Universität Zürich (CH) | 2012-12-06 | — | — | WO | claimed |
| US-10858358-B2 | S1PR2 antagonists and uses therefor | DALHOUSIE UNIVERSITY (CA) | 2020-12-08 | — | — | US | disclosed |
| US-20190127372-A1 | S1PR2 ANTAGONISTS AND USES THEREFOR | DALHOUSIE UNIVERSITY (CA) | 2019-05-02 | — | — | US | disclosed |
| US-10058543-B2 | Treatment of familial exudative vitreoretinopathy through S1PR2 inhibition | DALHOUSIE UNIVERSITY (CA) | 2018-08-28 | — | — | US | disclosed |
| US-20180141942-A1 | S1PR2 ANTAGONISTS AND USES THEREFOR | DALHOUSIE UNIVERSITY (CA) | 2018-05-24 | — | — | US | disclosed |
| US-20170135997-A1 | TREATMENT OF FAMILIAL EXUDATIVE VITREORETINOPATHY THROUGH S1PR2 INHIBITION | DALHOUSIE UNIVERSITY (CA) | 2017-05-18 | — | — | US | disclosed |
| US-20140187550-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2014-07-03 | — | — | US | disclosed |
| US-20140187550-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2014-07-03 | — | — | US | disclosed |
| US-20140187550-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2014-07-03 | — | — | US | disclosed |
| US-8633211-B2 | Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2014-01-21 | — | — | US | disclosed |
| US-8633211-B2 | Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2014-01-21 | — | — | US | disclosed |
| US-8633211-B2 | Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2014-01-21 | — | — | US | disclosed |
| WO-2012164103-A2 | BLOCKERS OF THE NOGO-A S1PR PATHWAY FOR THE TREATMENT OF DISEASES CHARACTERIZED BY NEURONAL DAMAGE AND LACK OF SUBSEQUENT REPAIR | Universität Zürich (CH) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012164103-A2 | BLOCKERS OF THE NOGO-A S1PR PATHWAY FOR THE TREATMENT OF DISEASES CHARACTERIZED BY NEURONAL DAMAGE AND LACK OF SUBSEQUENT REPAIR | Universität Zürich (CH) | 2012-12-06 | — | — | WO | disclosed |
| US-20100113774-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2010-05-06 | — | — | US | disclosed |
| US-20100113774-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2010-05-06 | — | — | US | disclosed |
| US-20100113774-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2010-05-06 | — | — | US | disclosed |
| WO-2008107436-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858358-B2 | S1PR2 antagonists and uses therefor | S1PR2, S1PR4, S1PR1 | CNR2 257/4885KDM4E 1437/4885MEN1 2563/4885 |
| US-20190127372-A1 | S1PR2 ANTAGONISTS AND USES THEREFOR | S1PR2, S1PR4, S1PR1 | CNR2 214/4885KDM4E 1060/4885MEN1 1365/4885 |
| US-10058543-B2 | Treatment of familial exudative vitreoretinopathy through S1PR2 inhibition | S1PR2, S1PR3, S1PR4 | CNR2 1002/4885KDM4E 3543/4885MEN1 2959/4885 |
| US-20180141942-A1 | S1PR2 ANTAGONISTS AND USES THEREFOR | S1PR2, S1PR4, S1PR1 | CNR2 214/4885KDM4E 1060/4885MEN1 1365/4885 |
| US-20100113774-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | S1PR3, S1PR1, S1PR2 | CNR2 48/4885KDM4E 3052/4885MEN1 3098/4885 |
| US-20170135997-A1 | TREATMENT OF FAMILIAL EXUDATIVE VITREORETINOPATHY THROUGH S1PR2 INHIBITION | S1PR2, S1PR3, S1PR4 | CNR2 1002/4885KDM4E 3543/4885MEN1 2959/4885 |
| US-20140187550-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | S1PR3, S1PR1, S1PR2 | CNR2 52/4885KDM4E 2815/4885MEN1 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.